Overview

A Study of the Safety and Efficacy of Single-agent Carlumab (an Anti-Chemokine Ligand 2 [CCL2]) in Participants With Metastatic Castrate-Resistant Prostate Cancer

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and effectiveness of the study drug carlumab in participants with metastatic castrate-resistant prostate cancer (cancer of the gland that makes fluid that aids movement of sperm).
Phase:
Phase 2
Details
Lead Sponsor:
Centocor Research & Development, Inc.